Vita Life Sciences Limited

VLS

AU000000VLS8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:33:55 2024-06-27 pm EDT			5-day change	1st Jan Change
2.28 ^AUD	0.00%		-4.20%	+28.09%

Jun. 14	Vita Life Sciences Issues H1 Sales Guidance of AU$39 Million to AU$40 Million	MT
Jun. 13	Vita Life Sciences Limited Provides Earnings Guidance for Half Year Ending June 30, 2024	CI

Vita Life Sciences Limited announces an Equity Buyback for 8,361,571 shares, representing 15% of its issued share capital.

May 21, 2024 at 11:02 pm EDT

Vita Life Sciences Limited (ASX:VLS) announces a share repurchase program. Under the program, the company will repurchase up to 8,361,571 shares, representing 15% of its issued share capital. The plan will be valid up to May 22, 2025.

As of May 22, 2024, the company has 55,743,808 shares in issue.

Latest news about Vita Life Sciences Limited

Vita Life Sciences Issues H1 Sales Guidance of AU$39 Million to AU$40 Million	Jun. 13	MT
Vita Life Sciences Limited Provides Earnings Guidance for Half Year Ending June 30, 2024	Jun. 13	CI
Vita Life Sciences Limited announces an Equity Buyback for 8,361,571 shares, representing 15% of its issued share capital.	May. 21	CI
Vita Life Sciences Limited authorizes a Buyback Plan.	May. 21	CI
Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 25	CI
Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023	Dec. 14	CI
Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023	23-08-24	CI
Vita Life Sciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director	23-08-01	CI
Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending 30 June 2023	23-06-25	CI
Vita Life Sciences Limited announces an Equity Buyback for 8,475,692 shares, representing 15% of its issued share capital.	23-05-09	CI
Vita Life Sciences Limited's Equity Buyback announced on May 11, 2022, has expired with 208,000 shares, representing 0.37% for AUD 0.34 million.	23-05-08	CI
Vita Life Sciences Limited authorizes a Buyback Plan.	23-05-08	CI
Vita Life Sciences Limited Announces Demise of Gregory Ralph, Non-Executive Director	23-04-11	CI
Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2022, Payable on April 14, 2023	23-02-23	CI
Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022	22-11-28	CI
Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022	22-09-21	CI
Vita Life Sciences Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022	22-08-26	CI
Vita Life Sciences Expects Higher H1 Sales, Pretax Profit	22-06-03	MT
Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022	22-06-03	CI
Vita Life Sciences Limited announces an Equity Buyback for 8,325,392 shares, representing 15% of its issued share capital.	22-05-11	CI
Vita Life Sciences Limited's Equity Buyback announced on May 28, 2021, has expired.	22-05-10	CI
Vita Life Sciences Limited authorizes a Buyback Plan.	22-05-10	CI

Chart Vita Life Sciences Limited

Duration

Period

More charts

Company Profile

Vita Life Sciences Limited (Vita Life) is a pharmaceutical and healthcare company. The Company is involved in formulating, packaging, sales and distributing vitamins and supplements. Its core business is the development and distribution of over-the-counter (OTC) medicines, as well as complementary and alternative medicines, dietary supplements and health foods under various brand names throughout Australia, Malaysia, Singapore, Thailand, Vietnam, China and Indonesia. Its brand portfolio includes Herbs of Gold, VitaHealth, VitaScience and VitaLife. Herbs of Gold brand produces premium herbal, mineral, vitamin and superfood products. VitaHealth brand offers a comprehensive range of nutritional products that cater to every health need, from inner wellness to outer radiance. VitaScience is a vivacious nutritional supplement brand that offers practitioner strength quality formulations. Its subsidiaries include Vita Healthcare Asia Pacific Sdn Bhd, Herbs of Gold Sdn Bhd and others.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VITA LIFE SCIENCES LIMITED	+28.09%	85.66M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B